# NewAmsterdam Pharma Company N.V. share price today (NewAmsterdam Pharma Company N.V., NAMS)

> NewAmsterdam Pharma Company N.V.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. NAMS · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/nams

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $18.89 (−48.6% in a year)
- Revenue (Jun 2026): $3.7 M (−80.7% on a year ago)
- Profit (Jun 2026), incl. one-off: −$64.1 M (one-off item, see below)
- Operating margin: −1,752.6% (−1,566.5 points on a year ago)
- ROE: −30%, FY25
- ROIC: −21.5%, against a 5.0% cost of capital: −26.5 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the NewAmsterdam Pharma Company N.V. share price today? NewAmsterdam Pharma Company N.V.'s share price was $18.89 at the close on 5 November 2026. It has been falling for 2 weeks. That is 36.1% below its average price over the last 200 trading days. In the last 52 weeks it traded between $19 and $41, and at that close it was at the low of that range. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 26 weeks running. Over the last 5.7 years the share price moved +78% while the S&P 500 moved +87%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 8 May 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does NewAmsterdam Pharma Company N.V. pay? NewAmsterdam Pharma Company N.V. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is NewAmsterdam Pharma Company N.V. on? NewAmsterdam Pharma Company N.V. is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is NewAmsterdam Pharma Company N.V. profitable? NewAmsterdam Pharma Company N.V. posted a net loss of $64.1 M in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of $204 M. That loss is 1,732.9% of the quarter's revenue. The same quarter a year earlier lost $17.4 M. 12 of the last 12 reported quarters were loss-making. Read this profit with care: at −$64.1 M it is bigger than the quarter's whole revenue of $3.7 M. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −1,752.6% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does NewAmsterdam Pharma Company N.V. make, and is it growing? NewAmsterdam Pharma Company N.V. reported $3.7 M of revenue in the Jun 2026 quarter, −80.7% on the same quarter a year earlier. Over 3 years it has grown −39.7% a year on average. The last full year, FY25, came in at $22.5 M. The last four reported quarters add to $7.1 M. The quarterly figures for FY22 do not add up to the full-year total on file, so those quarters are left out of the charts and sums. FY25 revenue was $22.5 M, −50.6% on the year before. Recent pace: the last four quarters grew −69.3% on average, against −39.7% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −88.9%, against −2.1% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does NewAmsterdam Pharma Company N.V. keep? NewAmsterdam Pharma Company N.V.'s operating margin was −1,752.6% in the Jun 2026 quarter, 1,566.5 percentage points lower than the same quarter a year ago. Across 4 years it has been between −1,298.6% and −3.5%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −1,566.5 percentage points on the year while gross margin changed +0.0 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is NewAmsterdam Pharma Company N.V.'s profit turning into cash? NewAmsterdam Pharma Company N.V.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $148 M of cash, against −$204 M of profit. After $246 K of spending on assets, free cash was −$148 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does NewAmsterdam Pharma Company N.V.'s cash go? NewAmsterdam Pharma Company N.V. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $942 K on assets over the last 3 years. Averaged over those years that is 1.4% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $942 K over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is NewAmsterdam Pharma Company N.V.'s P/E ratio, and how does it compare with its own history? NewAmsterdam Pharma Company N.V. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values NewAmsterdam Pharma Company N.V. at 100.3× its FY25 revenue of $22.5 M. The P/E comes back here once profit turns positive. ## Is the NewAmsterdam Pharma Company N.V. business getting better or worse? NewAmsterdam Pharma Company N.V.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 10 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does NewAmsterdam Pharma Company N.V. earn on its capital? NewAmsterdam Pharma Company N.V. earned a ROE of −30% in FY25. That is up from a low of −61% in FY23. Its return on capital used (ROIC) is 26.5 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −905.7% net margin and 0.03× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −905.7% net margin × 0.03× asset turnover × 1.13× leverage (assets divided by equity) ≈ −30.7% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −21.5% − 5.0% = −26.5 percentage points. The 5.0% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does NewAmsterdam Pharma Company N.V. have too much debt? NewAmsterdam Pharma Company N.V. has total debt of $82.0 K against shareholder equity of $631 M as of Jun 2026, so its debt is 0.00× its equity, which is very little. Year by year, that ratio went from 0.00 in FY21 to 0.00 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the NewAmsterdam Pharma Company N.V. shareholding pattern? We have no ownership or short-position figures for NewAmsterdam Pharma Company N.V., so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 8.3 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. ## How far is NewAmsterdam Pharma Company N.V. from balance-sheet trouble? For NewAmsterdam Pharma Company N.V., the Z-score is 27.61. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 27.61 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does NewAmsterdam Pharma Company N.V. rank in its industry? There is no score against its industry: NewAmsterdam Pharma Company N.V. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is NewAmsterdam Pharma Company N.V. compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to NewAmsterdam Pharma Company N.V. in size? NewAmsterdam Pharma Company N.V. is the 68th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Beam Therapeutics Inc., Xencor, Inc. and Arcus Biosciences, Inc. Just below it: Celldex Therapeutics, Inc., Septerna, Inc. and Recursion Pharmaceuticals, Inc. ### Biotechnology companies close in size

1. [Beam Therapeutics Inc.](https://www.sectoralpha.in/us/stocks/beam) $2.6 billion
2. [Xencor, Inc.](https://www.sectoralpha.in/us/stocks/xncr) $2.6 billion
3. [Arcus Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/rcus) $2.5 billion
4. NewAmsterdam Pharma Company N.V. $2.3 billion
5. [Celldex Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/cldx) $2.2 billion
6. [Septerna, Inc.](https://www.sectoralpha.in/us/stocks/sepn) $2.2 billion
7. [Recursion Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/rxrx) $2.2 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Pebblebrook Hotel Trust](https://www.sectoralpha.in/us/stocks/peb) $2.5 billion · REIT - Hotel & Motel
2. [Boyd Group Services Inc.](https://www.sectoralpha.in/us/stocks/bgsi) $2.5 billion · Auto & Truck Dealerships
3. NewAmsterdam Pharma Company N.V. $2.5 billion
4. [Pediatrix Medical Group, Inc.](https://www.sectoralpha.in/us/stocks/md) $2.5 billion · Medical Care Facilities
5. [LTC Properties, Inc.](https://www.sectoralpha.in/us/stocks/ltc) $2.5 billion · REIT - Healthcare Facilities

## What else do people ask about NewAmsterdam Pharma Company N.V.? ### What were NewAmsterdam Pharma Company N.V.'s latest quarterly results? NewAmsterdam Pharma Company N.V. reported revenue of $3.7 M and a net loss of $64.1 M for the Jun 2026 quarter. Earnings per share were −$0.52. The operating margin was −1,752.6%, 1,566.5 percentage points lower than a year earlier (as of 5 November 2026). ### What is NewAmsterdam Pharma Company N.V.'s market cap? NewAmsterdam Pharma Company N.V.'s market capitalisation is $2.3 B at a stock price of $18.89. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is NewAmsterdam Pharma Company N.V. performing? NewAmsterdam Pharma Company N.V.'s share price has been falling for 2 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 26 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will NewAmsterdam Pharma Company N.V.'s stock price go up? This page does not forecast NewAmsterdam Pharma Company N.V.'s stock price. What it shows instead: the stock price is $18.89, and it has been falling for 2 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Where is NewAmsterdam Pharma Company N.V. in its business cycle? NewAmsterdam Pharma Company N.V.'s FY25 operating margin was −1,002.9%, against a 4-year range of −1,298.6% to −3.5%: the low end of its own range, which is often where recoveries start. The latest quarter was −1,752.6%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the NewAmsterdam Pharma Company N.V. story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is NewAmsterdam Pharma Company N.V. a stock worth studying right now? What the numbers show: NewAmsterdam Pharma Company N.V.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.